VEXAS综合征：一种被忽视的威胁。 - Suppr

VEXAS Syndrome: An Overlooked Threat.

作者信息

Uğurlu Serdal, Kılıç Berkay

机构信息

Division of Rheumatology, Department of Internal Medicine, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye.

Department of Internal Medicine, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye.

出版信息

Balkan Med J. 2025 May 5;42(3):185-187. doi: 10.4274/balkanmedj.galenos.2025.2025-170425.

DOI:10.4274/balkanmedj.galenos.2025.2025-170425

PMID:40326802

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12060598/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5488/12060598/3a3547a1c9bd/BalkanMedJ-42-3-185-figure-1.jpg

相似文献

VEXAS Syndrome: An Overlooked Threat.

Balkan Med J. 2025 May 5;42(3):185-187. doi: 10.4274/balkanmedj.galenos.2025.2025-170425.

VEXAS Syndrome: A Novelty in MDS Landscape.

Diagnostics (Basel). 2022 Jun 29;12(7):1590. doi: 10.3390/diagnostics12071590.

[Clinical and genetic features of MDS associated with VEXAS syndrome].

Rinsho Ketsueki. 2024;65(4):255-264. doi: 10.11406/rinketsu.65.255.

Thrombotic manifestations of VEXAS syndrome.

Semin Hematol. 2021 Oct;58(4):230-238. doi: 10.1053/j.seminhematol.2021.10.006. Epub 2021 Oct 25.

VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field.

Leuk Lymphoma. 2024 Sep;65(9):1245-1257. doi: 10.1080/10428194.2024.2349950. Epub 2024 May 21.

VEXAS syndrome.

Int J Hematol. 2024 May 31. doi: 10.1007/s12185-024-03799-9.

VEXAS syndrome: Current clinical, diagnostic and treatment approaches.

Intractable Rare Dis Res. 2023 Aug;12(3):170-179. doi: 10.5582/irdr.2023.01020.

Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.

Br J Haematol. 2022 Feb;196(4):969-974. doi: 10.1111/bjh.17893. Epub 2021 Oct 14.

Targeting enhanced cell death represents a potential therapeutic strategy for VEXAS syndrome.

Rheumatol Adv Pract. 2024 May 22;8(2):rkae065. doi: 10.1093/rap/rkae065. eCollection 2024.

VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis.

Arthritis Rheumatol. 2022 Apr;74(4):665-670. doi: 10.1002/art.41992. Epub 2022 Mar 3.

本文引用的文献

Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry.

Rheumatology (Oxford). 2025 Jun 1;64(6):3872-3878. doi: 10.1093/rheumatology/keae530.

Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome.

Hemasphere. 2024 Jul 30;8(8):e129. doi: 10.1002/hem3.129. eCollection 2024 Aug.

Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis.

Bone Marrow Transplant. 2024 Oct;59(10):1423-1427. doi: 10.1038/s41409-024-02375-3. Epub 2024 Jul 26.

Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.

Ann Rheum Dis. 2024 Sep 30;83(10):1358-1367. doi: 10.1136/ard-2024-225640.

Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports.

Rheumatology (Oxford). 2024 Oct 1;63(10):2694-2700. doi: 10.1093/rheumatology/keae123.

Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review.

Rheumatol Int. 2024 Jul;44(7):1219-1232. doi: 10.1007/s00296-023-05513-0. Epub 2023 Dec 21.

Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about mosaicism.

Ann Rheum Dis. 2023 Dec;82(12):1594-1605. doi: 10.1136/ard-2023-224460. Epub 2023 Sep 4.

VEXAS Syndrome-Review.

Glob Med Genet. 2023 Jul 10;10(3):133-143. doi: 10.1055/s-0043-1770958. eCollection 2023 Sep.

How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies.

Rheumatology (Oxford). 2023 Nov 2;62(11):3518-3525. doi: 10.1093/rheumatology/kead240.

Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.

JAMA. 2023 Jan 24;329(4):318-324. doi: 10.1001/jama.2022.24836.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

VEXAS Syndrome: An Overlooked Threat.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献